Wearable device for managing Graves' disease medication
Treatments studied
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a wearable device called Glandy HYPER that helps doctors adjust your antithyroid medication dose for Graves' disease. It may offer a more precise and convenient way to manage your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 22 years or older.
- You have been recently diagnosed with Graves' disease or still have high thyroid hormone levels despite treatment.
- Your diagnosis is confirmed with a blood test showing high thyroid hormones and a positive TSH-receptor antibody test.
- You are willing and able to use the Glandy HYPER wearable device.
- You are not taking or needing propylthiouracil (PTU), and if you are on methimazole, you can stop it before starting the study.
- You do not have heart conditions like arrhythmia or heart failure, and you are not taking heart-rate-affecting medications (except short-acting beta-blockers for symptoms).
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use birth control and have pregnancy tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a computer program called DigiThy that helps doctors adjust your methimazole dose compared to standard care. The goal is to control your thyroid hormone levels more effectively and safely.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
This study tests an artificial intelligence tool designed to help detect overactive thyroid conditions (thyrotoxicosis). It may be an option for people with Graves' disease, whether newly diagnosed or currently in treatment.
This study tests whether efgartigimod, an injectable medication given under the skin, can help control overactive thyroid (Graves' disease) in adults already taking methimazole or carbimazole. The goal is to see if it reduces thyroid antibodies and improves thyroid hormone levels.
This study tests a new medicine, BHV-1300, to see if it can safely and effectively reduce the overactive thyroid caused by Graves' disease, an autoimmune condition. It may offer a new option for people who haven't had certain prior treatments.
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
Hear when a new Hyperthyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.